Literature DB >> 23716361

Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis.

Mert Erkan1.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a notoriously therapy-resistant desmoplastic tumour. Antifibrotic therapy is shown to increase drug delivery in the preclinical setting. However, this approach can be a double-edged sword: first, PDAC is not uniform and some types of (dormant) stroma may in fact be protective; second, conventional chemotherapeutics are not powerful enough to eradicate all cancer cells in the tumour, therefore breaking down the stromal wall non-selectively may also lead to the increased dissemination of cancer cells. Recently, Kadaba et al have analysed the impact of the stromal cells in pancreatic, oesophageal and skin cancers, in bio-engineered, physiomimetic organotypic cultures. These authors show that the maximal effect on increasing cancer cell proliferation and invasion, as well as decreasing cancer cell apoptosis, occurs when pancreatic stellate cells constitute the majority of the cellular population in a three-dimensional (3D) model. This work may be instrumental for better understanding the types of stoma in PDAC before eliminating it non-selectively.
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  evolution; hypoxia; microenvironment; pancreatic stellate cells; stroma; therapy resistance

Mesh:

Year:  2013        PMID: 23716361     DOI: 10.1002/path.4213

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  21 in total

Review 1.  A review on myricetin as a potential therapeutic candidate for cancer prevention.

Authors:  Nazia Afroze; Sreepoorna Pramodh; Arif Hussain; Madiha Waleed; Kajal Vakharia
Journal:  3 Biotech       Date:  2020-04-24       Impact factor: 2.406

2.  Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression.

Authors:  Jiyoon Lee; Salvatore Condello; Bakhtiyor Yakubov; Robert Emerson; Andrea Caperell-Grant; Kiyotaka Hitomi; Jingwu Xie; Daniela Matei
Journal:  Clin Cancer Res       Date:  2015-06-03       Impact factor: 12.531

Review 3.  Pancreatic biomarkers: could they be the answer?

Authors:  Angela Lamarca; Jaime Feliu
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

4.  Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice.

Authors:  Huan Meng; Yang Zhao; Juyao Dong; Min Xue; Yu-Shen Lin; Zhaoxia Ji; Wilson X Mai; Haiyuan Zhang; Chong Hyun Chang; C Jeffrey Brinker; Jeffrey I Zink; Andre E Nel
Journal:  ACS Nano       Date:  2013-10-28       Impact factor: 15.881

5.  Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.

Authors:  Camille Duluc; Siham Moatassim-Billah; Mounira Chalabi-Dchar; Aurélie Perraud; Rémi Samain; Florence Breibach; Marion Gayral; Pierre Cordelier; Marie-Bernadette Delisle; Marie-Pierre Bousquet-Dubouch; Richard Tomasini; Herbert Schmid; Muriel Mathonnet; Stéphane Pyronnet; Yvan Martineau; Corinne Bousquet
Journal:  EMBO Mol Med       Date:  2015-06       Impact factor: 12.137

6.  The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma.

Authors:  Lai Mun Wang; Michael A Silva; Zenobia D'Costa; Robin Bockelmann; Zahir Soonawalla; Stanley Liu; Eric O'Neill; Somnath Mukherjee; W Gillies McKenna; Ruth Muschel; Emmanouil Fokas
Journal:  Oncotarget       Date:  2016-01-26

Review 7.  The immune system in cancer metastasis: friend or foe?

Authors:  Louise M E Janssen; Emma E Ramsay; Craig D Logsdon; Willem W Overwijk
Journal:  J Immunother Cancer       Date:  2017-10-17       Impact factor: 13.751

Review 8.  Pancreatic Cancer Chemoresistance to Gemcitabine.

Authors:  Manoj Amrutkar; Ivar P Gladhaug
Journal:  Cancers (Basel)       Date:  2017-11-16       Impact factor: 6.639

Review 9.  Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression.

Authors:  Radim Moravec; Rao Divi; Mukesh Verma
Journal:  World J Gastrointest Oncol       Date:  2017-06-15

Review 10.  KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment.

Authors:  Daniel Zeitouni; Yuliya Pylayeva-Gupta; Channing J Der; Kirsten L Bryant
Journal:  Cancers (Basel)       Date:  2016-04-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.